Evidence map›Paper›PMID 30189890›Full record

ArticleArthritis research & therapy2018

Arhalofenate acid inhibits monosodium urate crystal-induced inflammatory responses through activation of AMP-activated protein kinase (AMPK) signaling.

Charles McWherter, Yun-Jung Choi, Ramon L Serrano, Sushil K Mahata, Robert Terkeltaub, Ru Liu-Bryan

Open access · goldAbstract read
In one paragraph

Article in Arthritis research & therapy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 1 pooled it
1.9field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 1 synthesis or guideline pooled it, 46 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Gout and NLRP3 Inflammasome Biology.Arthritis & rheumatology (Hoboken, N.J.) · 2025
    Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. The NADase CD38 is a central regulator in gouty inflammation and a novel druggable therapeutic target.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2024
    Article
  10. The Evolving Landscape of Gout in the Female: A Narrative Review.Gout, urate, and crystal deposition disease · 2023
    Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Active Flavonoids FromFrontiers in pharmacology · 2021
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Charles McWherterCymaBay Therapeutics, Inc., Newark, California, USA.
Yun-Jung ChoiCymaBay Therapeutics, Inc., Newark, California, USA.
Ramon L SerranoVA San Diego Healthcare System, 111K, 3350 La Jolla Village Drive, San Diego, CA, 92161, USA.
Sushil K MahataVA San Diego Healthcare System, 111K, 3350 La Jolla Village Drive, San Diego, CA, 92161, USA.
Robert TerkeltaubVA San Diego Healthcare System, 111K, 3350 La Jolla Village Drive, San Diego, CA, 92161, USA.
Ru Liu-BryanVA San Diego Healthcare System, 111K, 3350 La Jolla Village Drive, San Diego, CA, 92161, USA. ruliu@ucsd.edu.ORCID 0000-0002-9611-8163
University of California San Diego · USCymaBay Therapeutics (United States) · US

Funding

The Effects of Urate Lowering Therapy on Inflammation, Endothelial function, andP50AR060772 · NIAMS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI SINGH, JASVINDER A · 2012 to 2021
$12.8M
Innate Inflammation in OsteoarthritisI01BX001660 · VA · VA SAN DIEGO HEALTHCARE SYSTEM · PI TERKELTAUB, ROBERT A. · 2012 to 2020
–
ATP-Citrate Lyase As A Novel Metabolic Target for OsteoarthritisI01BX002234 · VA · VA SAN DIEGO HEALTHCARE SYSTEM · PI BRYAN, RU · 2015 to 2022
–
Catestatin improves glucose homeostasis and insulin sensitivity in diet-induced obese miceI01BX003934 · VA · VA SAN DIEGO HEALTHCARE SYSTEM · PI MAHATA, SUSHIL K · 2018 to 2021
–
BLRD VA I01 BX001660BLRD VA I01BX001660BLRD VA I01 BX002234BLRD VA I01BX002234BLRD VA I01 BX003934NIAMS NIH HHS P50 AR060772NIAMS NIH HHS P50 AR060772-6
6 · The paper itself

Abstract

backgroundArhalofenate acid, the active acid form of arhalofenate, is a non-agonist peroxisome proliferator-activated receptor γ (PPARγ) ligand, with uricosuric activity via URAT1 inhibition. Phase II studies revealed decreased acute arthritis flares in arhalofenate-treated gout compared with allopurinol alone. Hence, we investigated the anti-inflammatory effects and mechanisms of arhalofenate and its active acid form for responses to monosodium urate (MSU) crystals.

methodsWe assessed in-vivo responses to MSU crystals in murine subcutaneous air pouches and in-vitro responses in murine bone marrow-derived macrophages (BMDMs) by enzyme-linked immunosorbent assay (ELISA), SDS-PAGE/Western blot, immunostaining, and transmission electron microscopy analyses.

resultsOral administration of arhalofenate (250 mg/kg) blunted total leukocyte ingress, neutrophil influx, and air pouch fluid interleukin (IL)-1β, IL-6, and CXCL1 in response to MSU crystal injection (p < 0.05 for each). Arhalofenate acid (100 μM) attenuated MSU crystal-induced IL-1β production in BMDMs via inhibition of NLRP3 inflammasome activation. In addition, arhalofenate acid dose-dependently increased activation (as assessed by phosphorylation) of AMP-activated protein kinase (AMPK). Studying AMPKα1 knockout mice, we elucidated that AMPK mediated the anti-inflammatory effects of arhalofenate acid. Moreover, arhalofenate acid attenuated the capacity of MSU crystals to suppress AMPK activity, regulated expression of multiple downstream AMPK targets that modulate mitochondrial function and oxidative stress, preserved intact mitochondrial cristae and volume density, and promoted anti-inflammatory autophagy flux in BMDMs.

conclusionsArhalofenate acid is anti-inflammatory and acts via AMPK activation and its downstream signaling in macrophages. These effects likely contribute to a reduction of gout flares.

Indexed as

AcetamidesAMP-Activated Protein KinasesAnimalsBone Marrow CellsCells, CulturedInflammationInflammation MediatorsMiceMice, Inbred C57BLPhenylacetatesSignal TransductionUric AcidAcetamidesAMP-Activated Protein KinasesarhalofenateInflammation MediatorsPhenylacetatesUric AcidAMPKAutophagy fluxGoutInflammationMitochondria

Identifiers

PMID30189890
PMCPMC6127987
OpenAlexW2890713120

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.